Sign in to view content

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy

Michael J Allingham, MD, PhD

Video
Published 2022

Related

Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2022
Randomized Trial of Initiating Therapy With Aflibercept, Laser, or Observation for Eyes With Good Vision and Center-Involved Diabetic Macular Edema
Carl W. Baker, MD, FASRS
Updates from the Field
2019
Diabetic Retinopathy 2 Symposium
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more